Atomoxetine-Associated Hemospermia: A Case Report

View This PDF

NB: This article is only available as a PDF.

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Atomoxetine is the only nonstimulant medication approved by the U.S. Food and Drug Administration for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults. Since its approval in 2002, it has been widely prescribed and has been associated with a low overall incidence of adverse effects. The 4 most common adverse effects include dry mouth, insomnia, nausea, and erectile dysfunction. The following case report describes a novel adverse effect associated with atomoxetine—hemospermia.​

J Clin Psychiatry 2008;69(7):1189 [letter]